Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary

Status Recruiting

Clinical Trial Summary

This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis. To be included in the initial treatment of pulmonary tuberculosis patients, on the basis of standardized Western medicine treatment, BaidiZiyin Pills and ShenqiYifei Pills will be used to evaluate the clinical efficacy and safety of their products. 1. Evaluate the improvement of symptoms in the adjuvant treatment of newly treated pulmonary tuberculosis with BaidiZiyin Pill and ShenqiYifei Pill. 2. Explore the sputum negative conversion time and sputum negative conversion rate of BaidiZiyin Pill and ShenqiYifei Pill as adjunctive treatments for newly treated pulmonary tuberculosis. 3. Explore the protective effects of BaidiZiyin Pill and ShenqiYifei Pill on adverse reactions caused by chemotherapy.

Clinical Trial Description

1. Research drugs: Bai Di Zi Yin Wan and Shen Qi Yi Fei Wan. 2. Research objective: To evaluate the symptom improvement of Baidi Ziyin Pill and Shenqi Yifei Pill in the adjuvant treatment of newly treated pulmonary tuberculosis; Explore the sputum negative conversion time and sputum negative conversion rate of Baidi Ziyin Pill and Shenqi Yifei Pill as adjunctive treatments for newly treated pulmonary tuberculosis; Explore the protective effects of Baidi Ziyin Pill and Shenqi Yifei Pill on adverse reactions caused by chemotherapy. 3. Study design: A randomized, controlled, multicenter clinical study. 4. Clinical staging: re evaluation after listing. 5. Treatment plan: Experimental group: Take Bai Di Zi Yin Wan in the morning, 45 pills per time; Take 45 pills of Shenqi Yifei Pill per time at night, combined with a first-line anti tuberculosis regimen of 2HRZE Control group: Antituberculosis chemotherapy Recommended frontline anti tuberculosis regimen: 2HRZE Isoniazid (0.3g), rifampicin (0.45g for weight 50kg and below, 0.6g for weight 50kg and above), pyrazinamide (1.5g), ethambutol (0.75g for weight 50kg and below, 1.0g for weight 50kg and above), once a day, for a course of 8 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06403943
Study type	Interventional
Source	Beijing Chest Hospital
Contact	WENJUAN NIE, DR
Phone	+86 10 89509331
Email	94642975@qq.com
Status	Recruiting
Phase	Phase 4
Start date	May 29, 2023
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05738681` - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial	Phase 2/Phase 3
Recruiting	`NCT05526885` - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa	N/A
Completed	`NCT04369326` - Community Initiated Preventive Therapy for TB	N/A
Recruiting	`NCT04568967` - TB-CAPT EXULTANT - HIV	N/A
Completed	`NCT02337270` - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol	Phase 1
Not yet recruiting	`NCT06253715` - Shortened Regimen for Drug-susceptible TB in Children	Phase 3
Recruiting	`NCT04271397` - Immunological Biomarkers in Tuberculosis Management	N/A
Withdrawn	`NCT03639038` - Tuberculosis Diagnosis by Flow Cytometry
Completed	`NCT03199313` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid	Phase 1
Recruiting	`NCT04975178` - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa	Phase 3
Completed	`NCT04463680` - Rifampin and the Contraceptive Implant	Phase 4
Completed	`NCT03973970` - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting	`NCT04230395` - Alcohol Reduction Among People With TB and HIV in India	N/A
Completed	`NCT04874948` - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment	Phase 1
Active, not recruiting	`NCT02906007` - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV	Phase 1/Phase 2
Not yet recruiting	`NCT05917210` - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda	N/A
Not yet recruiting	`NCT05845112` - Start Taking Action For TB Diagnosis
Not yet recruiting	`NCT06017843` - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding	N/A
Active, not recruiting	`NCT02715271` - Study of TB Lesions Obtained in Therapeutical Surgery
Completed	`NCT02781909` - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms